Muromonab CD3. A review of its pharmacology and therapeutic potential

Drugs
P A Todd, R N Brogden

Abstract

Muromonab CD3 (Orthoclone OKT3, Orthoclone, OKT3) is the first monoclonal antibody to become available for therapy in humans. In effect it blocks all cytotoxic T cell function. Clinical trials show that muromonab CD3 is effective in reversing acute renal, hepatic, cardiac and combined kidney-pancreas transplant rejection episodes. It has also been shown to be effective in the treatment of rejections resistant to conventional treatment. As such it offers a significant alternative when no other therapeutic option remains open. Other clinical trials have shown that muromonab CD3 is more effective than high-dose corticosteroids in reversing first episodes of acute renal and hepatic rejection. Additionally, it appears effective as a prophylactic treatment against acute renal and cardiac rejection in the immediate post-transplantation period. Preliminary studies also indicate that it may be effective in preventing or reversing graft-versus-host disease in bone marrow transplant patients. The development of neutralising antibodies may limit the effectiveness of a second course of muromonab CD3 therapy in some patients. In conclusion, muromonab CD3 offers a significant new approach to immunosuppressive therapy and has provided a valuab...Continue Reading

Citations

Dec 1, 1996·Clinical Cardiology·A Blum, D Aravot
Oct 1, 1993·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·M Ferraresso, B D Kahan
Jan 10, 2013·Clinical Pharmacokinetics·Miroslav DostalekManoranjenni Chetty
Jan 1, 1995·Transplant International : Official Journal of the European Society for Organ Transplantation·K J ParlevlietP T Schellekens
Jul 1, 1991·The American Review of Respiratory Disease·H ShennibD Mulder
Jun 1, 1994·The Journal of Clinical Investigation·K J ParlevlietP T Schellekens
Dec 1, 1992·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·J M GrinoJ Alsina
Jun 1, 1992·Mayo Clinic Proceedings·M D McGoon, R P Frantz
Jan 1, 1991·Kidney International·R S GastonJ J Curtis
Jul 23, 2011·Journal of the American Academy of Dermatology·Yevgeniy BalagulaMario E Lacouture
Aug 28, 2009·Current Opinion in Biotechnology·Carrie EneverArmin Sepp
Dec 9, 2014·MAbs·Audrey E BakerMark L Chiu
May 26, 2007·Biotechnology Journal·Pavel K IvanovAnatoly Y Baryshnikov
May 25, 2013·Transplant International : Official Journal of the European Society for Organ Transplantation·Stuart C Sweet
Sep 1, 1996·Journal of Transplant Coordination : Official Publication of the North American Transplant Coordinators Organization (NATCO)·S L Smith
Sep 27, 2016·Toxins·Bryan D Fleming, Mitchell Ho
Aug 1, 1997·The Annals of Otology, Rhinology, and Laryngology·C J HartnickR V Smith
Aug 16, 2017·Journal of Clinical Laboratory Analysis·Zhanhu ZhangHaibo Li
Dec 1, 1990·DICP : the Annals of Pharmacotherapy·J RelloA Net
Dec 10, 1997·The Annals of Pharmacotherapy·M L Burk, K A Matuszewski
Dec 1, 1991·DICP : the Annals of Pharmacotherapy·W D Figg
Dec 19, 2019·International Journal of Molecular Sciences·Nicole TrierGunnar Houen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.